Functional genomic studies of aldo-keto reductases

J M Petrash1, B S Murthy, M Young

  • 1Departments of Ophthalmology and Visual Sciences and of Genetics, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8096, MO 63110, St. Louis, USA. petrash@vision.wustl.edu

Insights

Aldose reductase (AR) plays a role in diabetic complications. Researchers used yeast genomics to identify and characterize AR-like genes, finding two highly similar to human AR.

Area of Science:

  • Biochemistry
  • Genomics
  • Molecular Biology

Background:

  • Aldose reductase (AR) is implicated in diabetic complications, making it a drug target.
  • The precise physiological role of AR remains unestablished.
  • Understanding AR's function is crucial for early intervention in diabetic complications.

Purpose of the Study:

  • To investigate the physiological role of aldose reductase (AR) using functional genomics.
  • To identify and characterize AR-like genes in Saccharomyces cerevisiae (yeast).
  • To determine if yeast can serve as a model system for studying AR function.

Main Methods:

  • Utilized BLAST searches to identify AR-homologous genes in the yeast genome.
  • Cloned six identified yeast AR-like open reading frames (ORFs) into expression vectors.
  • Surveyed substrate and inhibitor specificities of four yeast AR-like enzymes.

Main Results:

  • Identified six AR-like genes in the S. cerevisiae genome with conserved catalytic residues.
  • Two yeast enzymes, YDR368Wp and YHR104Wp, showed significant similarity to human AR in activity.
  • Ongoing studies are investigating yeast strains with knockouts of these AR-like genes.

Conclusions:

  • Yeast harbors AR-like genes with conserved catalytic functions, suggesting potential for studying AR's physiological roles.
  • Yeast provides a tractable model system for functional genomics studies of AR and related enzymes.
  • Further characterization of yeast AR-like gene knockouts will elucidate their physiological significance.

Related Concept Videos

Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...